» Articles » PMID: 25691096

A Large-Scale Analysis of Genetic Variants Within Putative MiRNA Binding Sites in Prostate Cancer

Abstract

Unlabelled: Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role.

Significance: Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.

Citing Articles

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.

PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.


Exome Sequence Data of Eight SLC Transporters Reveal That and Variants Alter Metformin Pharmacokinetics and Glycemic Control.

Morales-Rivera M, Alemon-Medina R, Martinez-Hernandez A, Contreras-Cubas C, Altamirano-Bustamante N, Gomez-Garduno J Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459024 PMC: 11510168. DOI: 10.3390/ph17101385.


IsomiR-eQTL: A Cancer-Specific Expression Quantitative Trait Loci Database of miRNAs and Their Isoforms.

Moradi A, Whatmore P, Farashi S, Barrero R, Batra J Int J Mol Sci. 2022; 23(20).

PMID: 36293349 PMC: 9604134. DOI: 10.3390/ijms232012493.


Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer.

Hua X, Li Y, Pentaparthi S, McGrail D, Zou R, Guo L Cancer Res. 2022; 83(1):59-73.

PMID: 36265133 PMC: 9811166. DOI: 10.1158/0008-5472.CAN-20-0371.


Integrated Approaches to Identify miRNA Biomarkers Associated with Cognitive Dysfunction in Multiple Sclerosis Using Text Mining, Gene Expression, Pathways, and GWAS.

Prabahar A, Raja K Diagnostics (Basel). 2022; 12(8).

PMID: 36010264 PMC: 9406323. DOI: 10.3390/diagnostics12081914.


References
1.
Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A . Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res. 2000; 6(1):160-5. View

2.
Johnson A, Handsaker R, Pulit S, Nizzari M, ODonnell C, de Bakker P . SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008; 24(24):2938-9. PMC: 2720775. DOI: 10.1093/bioinformatics/btn564. View

3.
Fortier A, Holaday J, Liang H, Dey C, Grella D, Holland-Linn J . Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate. 2003; 56(3):212-9. DOI: 10.1002/pros.10256. View

4.
Muckstein U, Tafer H, Hackermuller J, Bernhart S, Stadler P, Hofacker I . Thermodynamics of RNA-RNA binding. Bioinformatics. 2006; 22(10):1177-82. DOI: 10.1093/bioinformatics/btl024. View

5.
Chen J, Yao D, Li Y, Chen H, He C, Ding N . Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 2013; 32(3):557-67. PMC: 3782554. DOI: 10.3892/ijmm.2013.1424. View